Encysive Goes on Sale | Chemical & Engineering News
Volume 85 Issue 30 | p. 17 | Concentrates
Issue Date: July 23, 2007

Encysive Goes on Sale

Department: Business | Collection: Green Chemistry

Encysive Pharmaceuticals has enlisted investment bank Morgan Stanley to help find a suitor after a series of setbacks for its lead product candidate. Last month, FDA issued a third "approvable" letter for Thelin, the Houston-based biotech firm's drug for high blood pressure in the pulmonary artery. The agency asked for more evidence of the drug's efficacy, further delaying its launch in the U.S. Encysive subsequently slashed its workforce by about 70% to 65 people to focus its remaining resources on getting Thelin to market in the U.S. This latest announcement from Encysive comes as Gilead Sciences prepares to launch its competing drug for pulmonary arterial hypertension, Letairis.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment